Pacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Recommendation of “Moderate Buy” by Analysts

Pacira BioSciences, Inc. (NASDAQ:PCRX) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $52.36.

A number of research firms recently weighed in on PCRX. TheStreet downgraded Pacira BioSciences from a “c” rating to a “d+” rating in a research report on Thursday, November 2nd. HC Wainwright cut their price target on shares of Pacira BioSciences from $63.00 to $57.00 and set a “buy” rating for the company in a research note on Monday, November 6th. Truist Financial cut their price target on shares of Pacira BioSciences from $60.00 to $55.00 and set a “buy” rating for the company in a research note on Thursday, August 3rd. Needham & Company LLC cut their price target on shares of Pacira BioSciences from $52.00 to $45.00 and set a “buy” rating for the company in a research note on Friday, November 3rd. Finally, TD Cowen upgraded shares of Pacira BioSciences from a “market perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research note on Thursday, August 3rd.

Pacira BioSciences Stock Down 0.8 %

PCRX stock opened at $27.67 on Tuesday. Pacira BioSciences has a twelve month low of $26.59 and a twelve month high of $50.11. The company has a market cap of $1.28 billion, a PE ratio of 307.44 and a beta of 0.76. The business’s 50-day simple moving average is $30.10 and its 200 day simple moving average is $35.40. The company has a quick ratio of 3.74, a current ratio of 4.78 and a debt-to-equity ratio of 0.62.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Rice Hall James & Associates LLC boosted its position in Pacira BioSciences by 8.7% in the 1st quarter. Rice Hall James & Associates LLC now owns 456,798 shares of the company’s stock valued at $34,863,000 after buying an additional 36,593 shares during the last quarter. Raymond James & Associates boosted its position in Pacira BioSciences by 2.3% in the 1st quarter. Raymond James & Associates now owns 35,299 shares of the company’s stock valued at $2,694,000 after buying an additional 791 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in Pacira BioSciences in the 1st quarter valued at $339,000. Natixis Advisors L.P. boosted its position in Pacira BioSciences by 22.6% in the 1st quarter. Natixis Advisors L.P. now owns 12,898 shares of the company’s stock valued at $984,000 after buying an additional 2,381 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its position in Pacira BioSciences by 55.3% in the 1st quarter. MetLife Investment Management LLC now owns 23,671 shares of the company’s stock valued at $1,807,000 after buying an additional 8,425 shares during the last quarter. Institutional investors own 99.73% of the company’s stock.

About Pacira BioSciences

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves.